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Abstract
Background: The collection of biomarker-based indicators of adult health and fitness is an important addition
to socioeconomic surveys since these indicators provide valuable insights into the biological functions, and
the complex causal pathways between socioeconomic environments and health of adult individuals. Other
than select Demographic and Health Surveys (DHS), there are almost no population-based sources of
biomarker-based indicators of adult health in sub-Saharan Africa (SSA), where most population-based
biologic data are focused on HIV, other STDs, malaria, or nutritional status. While infectious diseases---such
as HIV and malaria---attract the majority of research and NGOs attention in sub-Saharan Africa, there is an
important need to understand the general determinants of adult health in SSA since the region will rapidly age
in the next decades in ways that are significantly different from the aging patterns in other developing regions
due to the AIDS epidemic, and chronic diseases will increasingly become relevant for understanding the
health of sub-Saharan populations. Methods and Design: We document our protocol for the collection of
biomarker-based health indicators as a pilot project within the Malawi Longitudinal Study of Families and
Health (MLSFH), and we provide basic descriptive information about the study population and the collected
biomarker-based indicators of adult health obtained from respondents in rural Malawi. LabAnywhere kits
were used to obtain blood plasma from 980 adult men and women living in Balaka, the southern-most region
in rural Malawi. The procedure allows for the non-invasive collection of blood plasma, but has not been been
previously used in the context of a developing country. We collected biomarkers for inflammation and
immunity, lipids, organ function, and metabolic processes. We specifically collected wide-range CRP, total
cholesterol, LDL, HDL, total protein, urea, albumin, blood urea nitrogen, creatinine, random blood glucose
and HbA1c assays. Overall, the mean values of the biomarkers are below the lower limits of clinical guidelines
for adult populations in the U.S. and other developed countries, and only small proportions of the sample are
above the upper limits of the normal clinical ranges as defined by U.S. standards. The correlationional patterns
of the collected biomarkers are consistent with observations from developed countries, and the comparison
with other low-income populations such as the Tsimane in Bolivia or the Yakuts in Siberia show remarkably
similar age-specific patterns of the biomarkers despite differences in the mode of blood sampling. Discussion:
The MLSFH biomarker sample makes a potentially important contribution to understanding the health of the
adult populations in low income environments. The present study confirms that the collection of such
biomarkers using the LabAnywhere system is feasible in rural sub-Saharan contexts: the refusal rate was very
low in the MLSFH and following the procedures described above, only a small fraction of the biomarker
samples could not be analyzed by LabAnywhere. The system therefore provides an attractive alternative to the
collection of dried blood spots (DBS) and venous blood samples, providing a broader range of potential
biomarkers than DBS and being logistically easier than the collection of venous blood.
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Abstract
Background: The collection of biomarker-based indicators of adult health and fitness is an im-
portant addition to socioeconomic surveys since these indicators provide valuable insights into
the biological functions, and the complex causal pathways between socioeconomic environments
and health of adult individuals. Other than select Demographic and Health Surveys (DHS), there
are almost no population-based sources of biomarker-based indicators of adult health in sub-
Saharan Africa (SSA), where most population-based biologic data are focused on HIV, other
STDs, malaria, or nutritional status. While infectious diseases—such as HIV and malaria—attract
the majority of research and NGOs attention in sub-Saharan Africa, there is an important need to
understand the general determinants of adult health in SSA since the region will rapidly age in the
next decades in ways that are significantly different from the aging patterns in other developing
regions due to the AIDS epidemic, and chronic diseases will increasingly become relevant for
understanding the health of sub-Saharan populations.
Methods and Design: We document our protocol for the collection of biomarker-based health in-
dicators as a pilot project within the Malawi Longitudinal Study of Families and Health (MLSFH),
and we provide basic descriptive information about the study population and the collected bio-
marker-based indicators of adult health obtained from respondents in rural Malawi. LabAny-
where kits were used to obtain blood plasma from 980 adult men and women living in Balaka,
the southern-most region in rural Malawi. The procedure allows for the non-invasive collection
of blood plasma, but has not been been previously used in the context of a developing country.
We collected biomarkers for inflammation and immunity, lipids, organ function, and metabolic
processes. We specifically collected wide-range CRP, total cholesterol, LDL, HDL, total protein,
urea, albumin, blood urea nitrogen, creatinine, random blood glucose and HbA1c assays. Over-
all, the mean values of the biomarkers are below the lower limits of clinical guidelines for adult
populations in the U.S. and other developed countries, and only small proportions of the sample
are above the upper limits of the normal clinical ranges as defined by U.S. standards. The corre-
lationional patterns of the collected biomarkers are consistent with observations from developed
countries, and the comparison with other low-income populations such as the Tsimane in Bolivia
or the Yakuts in Siberia show remarkably similar age-specific patterns of the biomarkers despite
differences in the mode of blood sampling.
Discussion: The MLSFH biomarker sample makes a potentially important contribution to un-
derstanding the health of the adult populations in low income environments. The present study
confirms that the collection of such biomarkers using the LabAnywhere system is feasible in rural
sub-Saharan contexts: the refusal rate was very low in the MLSFH and following the procedures
described above, only a small fraction of the biomarker samples could not be analyzed by Lab-
Anywhere. The system therefore provides an attractive alternative to the collection of dried blood
spots (DBS) and venous blood samples, providing a broader range of potential biomarkers than
DBS and being logistically easier than the collection of venous blood.
1. INTRODUCTION
The collection of biomarker-based indicators of health as part of population-based sam-
ples has only recently become available for large-scale survey research, and it represents
a potentially important addition to socioeconomic surveys as these biomarker-based in-
dicators provide valuable insights into the biological function and the complex causal
pathways between socioeconomic environments and health [1–8]. Numerous studies
have established the relevance of biomarker collection for measuring the efficacy of im-
mune system function [9–11], malnutrition [12–14], and diabetes [15] on morbidity and
mortality [4]. Increasingly panel studies in industrialized countries (such as the Health
and Retirement Study (HRS) in the U.S. and the English Longitudinal Study of Aging
(ELSA) in the UK) are among the larger studies collecting biomarker-based health in-
dicators [4, 7, 16, 17]. However, very few population-based studies in the developing
world have followed suit, despite the considerable relevance of biomarker-based assess-
ments of health in the context of low income countries. Exceptions include several extant
isolated populations that are under intensive study—including the Cebu in the Philip-
pines [18] and the Tsimane in Bolivia [19, 20]—to investigate the evolution of human
immune response to various physiologic challenges and its relevance for human health
[21]. There are almost no population-based sources of general biomarker-based health
indicators in sub-Saharan Africa (SSA). Most population-based biomarker collections
in the region—for instance those conducted as part of Demographic and Health Sur-
veys (DHS) [22, 23]—have focused on HIV, other STDs, malaria and nutrition status
(e.g, anemia). While infectious diseases—such as HIV and malaria—often attract the
majority of research and NGOs attention in sub-Saharan Africa [24], there is an impor-
tant need to collect and analyze biomarkers of general health. Over the next decades
the adult populations in SSA will age rapidly in ways that will likely be distinct from
other developing countries due to the exposure to the AIDS epidemic [25–28]. Chronic
diseases will increasingly become relevant for understanding the health of sub-Saharan
populations. In this context, biomarker-based health indicators can provide important
information on normal physiological processes and signal pathogenic processes and/or
diseases [4, 17]. They can clarify how social and behavioral factors influence health [4],
and can help to identify pathways that are important for predicting morbidity and mor-
tality trends [29]. Moreover, because biomarker-based health information is not subject
to the same measurement errors as self-reported health indicators, biomarker-based mea-
sures of adult health may be particularly useful in surveys in developing countries where
the measurement of health is problematic and little is known about disease incidence,
duration, and prevalence or cause-specific mortality among adult and elderly individuals
[1].
The Malawi Longitudinal Study of Families and Health (MLSFH), a longitudinal
panel study in rural Malawi that provides a rare record of more than a decade’s dura-
tion of demographic, socioeconomic and health conditions in one of the world’s poorest
countries, has augmented its collection of socioeconomic data with biomarker-based in-
dicators of adult health in 2008–09. The MLSFH biomarker sample is a subset of about
900 MLSFH respondents and it provides 12 biomarker-based indicators of respondents’
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general health, focusing specifically on inflammation, cardiovascular risks, metabolic
processes and organ function. The aim of this paper is to document the protocol for the
biomarker data collection conducted for this sub-sample of MLSFH, and to provide ba-
sic descriptive information about the study population and the collected biomarker-based
indicators of health among adult individuals in a low income sub-Saharan population.
These MLSFH biomarkers provide new opportunities to study aspects of health and dis-
ease in a context characterized by a mature HIV/AIDS epidemic, high levels of poverty
and high levels morbidity and mortality.
2. BACKGROUND
Malawi is an opportune environment for studying epidemiologic and demographic tran-
sitions in real time. It is one of the poorest countries in the world, ranked 153 of 169
in terms of the human development index [30], with about 15% of its population con-
sidered “ultra-poor”, i.e., with an estimated food consumption below the minimum level
of dietary energy requirement (the proportion ultra-poor in Malawi has declined from
24% in 1998) [31]. Life expectancy at birth is estimated to be 47 years (44 years for
males/47 years for females) in 2009, with healthy life expectancy at birth estimated at
44 years in 2007 [32]. While the Malawian per capita income is below the sub-Saharan
average, Malawi is similar to other SSA countries and countries in the World Bank low
income group in terms of life expectancy, infant mortality, child malnutrition, access to
clean water, literacy and educational enrollment [32, 33]. In rural areas, such as the study
sites of the MLSFH, the majority of individuals engage in home production of crops, pri-
marily maize, squash, tomatoes, potatoes, nuts, dark green leafy vegetables, and fruit,
complemented by some market activities. The local diet is characterized by high intakes
of vegetables and grains (especially maize) and low consumption of protein-dense food,
especially animal-based proteins. Tuberculosis [34, 35], malaria [36, 37], and endemic
parasites (e.g., soil-transmitted helminths (STH) and schistosomia mansoni) also have a
relatively high prevalence [38–40]. Nearly 80% of all deaths in Malawi are caused by
infectious diseases including HIV/AIDS, malaria, TB, schistosomiasis, and nutritional
deficits [41]. Chronic conditions, on the other hand, continue to be relatively rare; in
2002, for example, cerebrovascular and cardiovascular diseases accounted for only 6.0%
of all deaths. This combination of low rates of chronic disease mortality but high levels of
communicable disease mortality are emblematic of the early stage of the epidemiologic
transition, i.e., the transformation of disease patterns that is (or has been) experienced by
all societies over time [42]. Sub-Saharan African countries, including Malawi, however
are distinct in their epidemiological transition due to the presence of the HIV/AIDS epi-
demic. The effects of the HIV/AIDS epidemic on the epidemiological transition is only
poorly understood [43–45]. Moreover, while HIV/AIDS is widespread, the vast major-
ity of the population—more than 85% of adults aged 15–49—is HIV negative [46], and
HIV-negative individuals also confront a high disease-risk environment characterized by
high levels of poverty, malaria, TB, endemic parasites, poor sanitation, limited access
to health care facilities, and, episodic malnutrition. Studies collecting biomarker-based
health indicators that represent both HIV+ and HIV– individuals, as is the case of the
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MLSFH biomarker data collection described below, are therefore important for evalu-
ating the health conditions of sub-Saharan populations, and the effects that population
aging and the HIV/AIDS epidemic have for population health in this region.
3. METHODS
3.1 Malawi Longitudinal Study of Families and Health (MLSFH)
The Malawi Longitudinal Study of Families and Health (MLSFH; formerly, Malawi Dif-
fusion and Ideational Change Project, MDICP) is a longitudinal panel data collection
with survey waves in 1998, 2001, 2004, 2006, 2008 and 2010 that is currently focused
on studying the mechanisms that individuals, families, households, and communities de-
velop and use in a poor rural setting to cope with the impacts of high morbidity and
mortality in their immediate living environment [47–58]. The MLSFH is implemented
in three sites in rural Malawi: Rumphi (in the northern region), Mchinji (in the central
region), and Balaka (in the southern region). These rural regions are similar in terms
of their overall economic context that is based on subsistence agriculture; however, the
study regions also reflect interesting heterogeneity in terms of marriage patterns [59],
religious affiliations [60], schooling [53, 61], patrilineal vs. matrilineal inheritance and
land-ownership, and HIV prevalence, thus reflecting a range of socioeconomic/health/
demographic conditions and permitting the evaluation of contextual effects, including
risk environments, on estimated relations pertaining to health and its behavioral and so-
cioeconomic determinants.
The MLSFH started in 1998 with a sample of 1,541 ever-married women aged 15–
49 and 1,065 of their spouses. In 2001, respondents were re-interviewed, along with
any new spouses since 1998. In 2004, the study added two new components to the
data-collection: a new additional sample of approximately 1,500 adolescents, and free
HIV testing and a voluntary counseling on the HIV test results for all respondents. The
MLSFH returned for a fourth wave of survey data collection and a second round of HIV
testing in 2006, and it followed-up in 2008 and 2010 with two additional rounds of wide-
ranging survey data for about 4,000 respondents aged between 21 (10th percentile) and 67
(90th percentile). Detailed descriptions of the MLSFH sample selection, data collection,
and data quality are provided on the project website http://www.malawi.pop.upenn.edu,
in a Special Collection of the online journal Demographic Research that is devoted to
the MLSFH [62], and in a recent follow-up publication that incorporates the 2004 and
2006 MLSFH data [48]. Comparisons with the Malawi Demographic and Health Survey
(DHS) showed that the MLSFH sample population is reasonably representative of the
rural Malawi population [48, 63].
Some core features of the MLSFH survey data that are particularly relevant for anal-
yses in connection with biomarker-based health indicators include: (a) measured weight
and height of respondents in 2008 to calculate the body mass index (BMI) as a simple, re-
liable, albeit crude indicator of body fat measures [64, 65]; repeated measures of mental
and physical health since 2006 using the SF12-scale; (b) repeated HIV tests (2004, 2006
and 2008) [58, 66] identifying 345 HIV+ individuals, and detailed measures of HIV risk
perceptions since 1998 [51, 52, 67]; (c) detailed demographic and socioeconomic data
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of respondents, including marital history and sexual-partnership histories; (d) compre-
hensive measures of economic and social shocks experienced by respondents and their
households, including mortality of family members, crop failures/income losses, changes
in health of individuals and their family members (since 1998); and (e) extensive infor-
mation on social networks and social capital, including participation in social groups
(since 1998) and unique information about family networks, intergenerational transfers
and resource sharing in extended family networks (since 2006) [54, 57, 68, 69].
3.2 MLSFH Biomarker Collection: Minimally Invasive Collection of Plasma in the
Field
We use the term “biomarker” as defined by Crimmins and colleagues [70], that is, as
an objectively measured trait that prior research has shown to be a reliable indicator of
normal biologic or pathologic processes that are common to human aging. The MLSFH
biomarker collection focused on blood serum indicators as these indicators are pertinent
to the study of health and aging in the sub-Saharan African context. Collecting such
biomarkers in surveys inevitably involves balancing the ease and cost with specimen
stability and assay reliability. These concerns are exacerbated in developing countries
with poor infrastructures for health care and transportation. Overcoming such obstacles
is necessary if we are to improve our understanding of population health in resource-
poor countries that are transitioning from an acute disease regime to one increasingly
dominated by chronic conditions [71, 72].
To date, the primary method for obtaining biomarkers in developing countries has
been dried blood spots (DBS). McDade pioneered these techniques for collecting and
storing small blood samples and developing assays for important biomarkers, such as
hsCRP, a marker of inflammation [29, 73, 74]. The infrastructure for processing DBS
assays has not kept pace with the large volume of DBS obtained in large, nationally rep-
resentative surveys. Moreover, the biomarkers that can be obtained from DBS remain
restricted. To avoid the complications associated with DBS, the MLSFH has tested a
new approach for collecting measures of population health and their adaptability to ex-
treme conditions in tropical zones. Our results indicate the reproducibility of biomarkers
obtained from the LabAnywhere (previously Demecal) system (LabAnywhere, Haarlem,
The Netherlands) [75], a new system for the collection of blood plasma that has been
used in other large-scale biomarker collections in developed countries [76–78]. This
biomarker collection as part of the MLSFH was approved by the IRB at the University
of Pennsylvania (May 9th, 2008) and by the Malawi National Health Sciences Research
Council (NHSRC) (December 8th, 2008).
The LabAnywhere kits used for the MLSFH biomarker collection require only a
few drops of blood harvested from a lancet puncture of a sanitized fingertip. A sponge
device is used for absorbing the drop of blood. After the sponge turns completely red, it
is dropped into a container with buffer fluid. A gentle swinging motion for 40 seconds
is necessary to release the dilution buffer. A filter is used to separate the red blood cells
from the plasma. The distinctive feature of this system is that the blood is pressed through
a patented filter that separates out plasma. Unlike a clinic based procedure for obtaining
blood plasma, the LabAnywhere system does not require the use of a centrifuge. The
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reliability, sensitivity, and specificity of the test kits have been demonstrated by LabAny-
where in the Netherlands, and the applications of test specific recovery factors yielded
a good correlation with results of venous blood samples [75]. In general, LabAnywhere
plasma samples are stable for 4 days at 4°C, 2–3 days at room temperature and 1 day at
37°C.
An important advantage of using the LabAnywhere kits for blood sampling is the
minor discomfort it causes to study participants. The kits offer an ideal combination
providing viable blood samples for analysis and a non-invasive means of collection. As
such, the LabAnywhere method offers several advantages over the other common means
of collecting blood samples such as dried blood spots (DBS) or venipuncture [17]. Blood
sample collection through DBS has several disadvantages including potential damage and
loss of viability caused by the drying of blood, and insufficient blood for testing provided
on the filter paper. While intravenous blood collection avoids the problems of DBS, it in-
volves a much more invasive procedure and requires collection by trained phlebotomists.
The LabAnywhere kit allows for the preparation of plasma from just one single drop of
blood at any location, at any time (e.g., at the homes of MLSFH respondents). Up to
16 assays can be done with this plasma. Because the plasma has been diluted, the Lab-
Anywhere analyser technology will measure very small amounts premitting this quantity
of assays. The disadvantages of the LabAnywhere method to collect and analyze blood
plasma compared to other approach are summarized and discussed in more details by
McDade [17].
There are numerous biomarkers of population health that could potentially inform
our understanding of adult health in rural Malawi. Those that we chose have demon-
strated analytic utility in studies of both, in developed countries [4]—notably in the U.S.
[79–83] and Japan [84]—and in developing countries, including resource-poor countries
such as Nigeria [85, 86], Amazonian Bolivia [20, 87], Mexico [88], the Philippines [89],
South Africa and other sub-Saharan populations [90, 91], Aboriginal Australia [92], and
indigenous Africans [93, 94].
The biomarkers that were collected as part of the MLSFH include: wide-range CRP
(wrCRP) as a measure of inflammation and the immune function [95]; a lipids panel
consisting of cholesterol, LDL, HDL, and triglycerides, as measures for risk factors for
cardiovascular disease; markers of renal function and clearance (total protein, uric acid,
albumin, urea/blood urea nitrogen (BUN), and creatinine); and circulating blood glu-
cose and HbA1c (only in cases when the blood glucose was above the normal range) as
markers of the metabolic function. Few, if any, biomarkers are free-standing reliable di-
agnostic tools, and neither are the ones listed above. Many of the MLSFH biomarkers are
standard blood work commonly ordered for mid-life adults. These are important mea-
sures for comparative purposes, but the environment in which participants live can amend
their interpretation. In the context of Malawi, low levels of total protein are more likely
to signal inadequate nutrition, rather than renal disease. Enteric infections in Malawi,
rare in the U.S., can impair intestinal transport of nutrients regardless of diet or anemia
in Malawi. Low levels of circulating glucose may be an important adaptation to unpre-
dictable energy inputs rather than a symptom of pathology, per se.
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Although the biomarkers collected as part of the MLSFH are well-known, we briefly
discuss our reasons for their selection, the critical levels used for obtaining indicators
of health risks, mostly for the U.S. and similar developed contexts, and the anticipated
relations of each biomarker to others we measure.
3.2.1 Lipids
Total cholesterol (TC), high-density lipoprotein (HDL), low density lipoprotein (LDL),
and triglycerides (TG) All lipids are fats that store energy for quick release, and to vary-
ing degrees, all lipids are recognized risk factors for cardiovascular disease in the devel-
oped world. For example, in the absence of other risk factors, the American Heart As-
sociation considers a total cholesterol reading of less than 200mg/dl desirable, 200-230
mg/dl borderline, and in excess of 240mg/dl as conveying a high risk for cardiovascu-
lar disease. The optimal level of HDL in a U.S. context is 50 mg/dl, but not less than
35 mg/dl, and less then 100mg/dl is recommended for LDL. Normal fasting triglyceride
levels in the U.S. are below 150 mg/dl; 150-199 mg/dl is considered borderline high, 200-
499 mg/dl high, and 500 mg/dl and greater very high [96]. However, because participants
from the Balaka region in Malawi live in rural environments, with food being produced at
relatively high energy expenditures but yielding few protein-dense calories, we expected
that the distribution of lipids among Malawi participants will be more concentrated at the
lower end of distributions than observed in European or U.S. populations.
3.2.2 Metabolic processes
Glucose and HbA1c: Random blood glucose, also known as a non-fasting blood sugar,
is a biomarker for the efficiency of the metabolic system. Glucose is the main source
of energy for the body. Insulin, the hormone that cells use to metabolize the glucose, is
produced in the pancreas. It is released into the blood in response to levels of circulating
glucose. A random blood glucose (RBG) tests has two advantages: it does not require
respondent fasting and it is less expensive. But because fasting is not a prerequisite
for the test, the RBG measure is less precise. The normal range for a random blood
sugar test is 70–100 mg/dl. At its most advanced stage, high blood sugar, if untreated,
increases the odds of renal and liver failure, as well as neuropathy, a malfunction of the
central nervous system, for which we did not collect a biomarker. HbA1c measures the
percentage of hemoglobin—a protein in red blood cells that carries oxygen—is coated
with sugar (glycated). Rather than measuring blood sugar levels at one point of time, the
HbA1C test shows an average blood sugar level for the past two to three months. HbA1C
below 5 percent is seen as normal level and a target, although it can range from 4.5 to 6
percent. People with diabetes are characterized by elevated HbA1C levels and for them
a level of about 7 percent is a target. In the MSFH biomaker data collection, HbA1c was
not measured for the entire sample, but only for those study participants who showed
elevated blood glucose levels (i.e., 12 study participants with a mean value of HbA1c of
5.53 and 0.71 std. dev.).
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3.2.3 Biomarkers of organ function
Creatinine: A major function of the kidneys is to filter out waste and water from the
blood. Creatinine is one of the waste products in the blood created by the normal break-
down of muscles; circulating levels of creatinine are fairly reliable indicator of the ef-
ficacy of kidney. Regardless of the etiology of the problem, as the kidneys become
impaired, creatinine levels in the blood rise because of poor clearance. Normal levels
of creatinine in the blood are approximately 0.6 to 1.2 mg/dl in adult males and 0.5 to
1.1 mg/dl in adult females. In malnourished persons or those who experience weight
loss or wasting, such as common in persons with HIV/AIDS or cancer, creatinine levels
may be surpassed. Crimmins and colleagues also note that serum creatinine is generally
less reliable than urinary creatinine [70]. Any condition that impairs the function of the
kidneys will increase creatinine level in the blood.
Albumin: Like creatinine, serum albumin is used to assess renal and liver function.
Albumin is the protein of highest concentration in the blood and maintains oncotic pres-
sure of blood to prevent its leakage into tissue. The normal (U.S.) range for of albumin is
3.5 to 5.5 mg/dl. A low albumin level is correlated with inflammation and malnutrition
while high levels signal dehydration. Low concentrations of albumin, even within the
normal range, have been positively related to coronary disease [97].
Total protein: Unlike fats and carbohydrates, proteins are not stored in the body.
They are continuously broken down (metabolized) into amino acids that are used as
building blocks for other proteins. The LabAnywhere test is a rough measure of all
the proteins found in the plasma, principally albumin and globulin. The normal range of
the test is 6.0 to 8.3mg/dl.
Uric Acid: Uric acid is produced in the body from purine metabolism and excreted
by the kidneys. Elevations and decreases in uric acid are associated with human dis-
ease and conditions; for instance, elevated uric acid is associated with gout, starvation,
metabolic syndrome or kidney stones, and decreased uric acid is associated with multiple
sclerosis. Normal values of uric acid range between 3.5 and 7.2 mg/dl.
Urea/Blood Urea Nitrogen (BUN): Blood carries proteins for use by cells throughout
the body. After the cells use the protein, the remaining waste products are returned to the
blood as urea, a compound containing nitrogen. Healthy kidneys take urea out of the
blood and send it to the bladder for excretion. If kidneys are not working well, the urea
stays in the blood. Normal blood contains 7 to 20 milligrams of urea per deciliter of
blood. A BUN result of more than 20 mg/dl indicates that kidneys are not functioning
normally. Other possible causes of an elevated BUN include dehydration, gastrointestinal
bleeding or heart failure.
3.2.4 Biomarkers of the Immune System
C-reactive protein (CRP): CRP is the most commonly used marker of inflammation and
infection. As an acute-phase response protein, CRP can increase as much as 1000-fold
in 24 hours. At elevated levels CPR indicates systemic infection or tissue damage, and
levels above 3.0 mg/l are generally considered as indicating a high risk for cardiovascular
disease. We assayed only this one biomarker of immune function. Were it not for budget
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constraint of this project, we would have preferred to include IL-6 that up-regulates CRP,
and an IGG panel that can be used to detect antibodies to specific diseases. Among the
commercially available CRP tests, we used the wide-range CRP (wrCRP) assay because
it detects levels of CRP in the range of 0.012–16.0 mg/l, and thus is sensitive to and
measures both very low and very high levels.
There are few studies of CRP in low-resource countries against which to compare
the distribution of CRP. In Malawi, we would expect median and mean levels of CRP to
be classified as high-risk range (≥ 3.0mg/l) for cardiovascular disease and related events,
such as myocardial infarction, or more relevantly, advancing HIV infection [98].
3.3 Health survey and anthropometric measurements
The biomarker data collection was accompanied by a brief personal questionnaire to
gather information on the respondent’s living environment, including sources of drinking
water, type of sanitation, prior malaria exposure, and regular use of insecticide-treated
bednets. We also asked participants when they last ate, what they had (particularly, pro-
tein and carbohydrates), about how much they consumed, if they have been recently
infected with malaria and/or other infectious diseases that dominate morbidity patterns
in Malawi. If the respondent was female, we also asked if she was currently pregnant.
3.4 Study population for MLSFH biomarker collection
For the MLSFH biomarker collection, we first identified one of the three MLSFH field-
work sites to conduct this biomarker collection (logistical and monetary considerations
precluded conducting this data collection in all three sites). Due to our particular interest
in the interaction between HIV and the biomarker measures, we chose the site with the
highest HIV prevalence, Balaka (in the southern region). Next, we drew our sample in
two stages. First, all respondents who were found HIV positive in a previous round of
the study were included in the sample. Next, in addition to the HIV positive respondents,
we drew a random sample of approximately 1500 respondents (aged ≥ 20 years) from
the 2500 total respondents in the MLSFH Balaka sample. Because of weather obstacles
we were able to re-contact 1,031 individuals. Of these, 49 respondents (4.7%) refused
to participate, and we collected biomarker specimens for 982 cases. Of the 982 cases,
approximately 60 cases had previously tested positive for HIV. Like the MLSFH study
population, the MLSFH biomarker sample is longitudinally linked across MLSFH sur-
vey waves and therefore providing sociecononomic and health data prior and after the
biomarker collection; it is also linked between husbands and wives, and the linkages
between parents and children are in process.
3.5 Field procedures, training and data management
The LabAnywhere test kits were delivered directly to Malawi in September 2008. A
test-run of all field procedures for about 70 cases was completed just prior to the full-
scale data collection in early January 2009, including the freezing protocol in Malawi,
the transport protocol, and the assays themselves. In this trial we were interested in how
well the integrity of the plasma samples was maintained and the reliability of the assays
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themselves. The actual field work commenced in mid January and was completed by
early February, 2009.
Because the administration of the LabAnywhere system in a developing country
context such as Malawi is ideally done using personnel trained in biomarker specimen
collection, the MLSFH biomarker collectors team consisted of 25 individuals who had
previously been trained by the Malawian Government in finger prick blood collection as
part of HIV voluntary counseling and testing. They underwent one-week of training in
the use of the kits prior to beginning biomarker collection in Balaka. Training included
the specific procedures for collecting samples using the LabAnywhere kit and for the
proper storage and transportation of the samples to the fieldwork headquarters; training
also included the ethical considerations of biomarker collection in the field, informed
consent, and the requirements for protecting respondents privacy and the confidentiality
of the collected data. All biomarker collectors participating in the training were required
to collect test samples that were sent to LabAnywhere for assessment. Only biomarker
collectors who produced usable samples from their test kits during the training were
certified by LabAnywhere and hired for the MLSFH biomarker collection on the main
sample.
Using village guides who knew the respondents, the MLSFH biomarker collectors
visited the home of the assigned respondent, obtained informed consent (either by sig-
nature or thumbprint from illiterate study participants) for the biomarker collection, and
then collected the plasma using the LabAnywhere kit. The informed consent process in-
volved a detailed discussion of the data collection process, the use of the biomarkers for
research purposes, the risk of study participation and the limited value of the collected
biomarkers for identifying any specific diseases the respondent might have. To protect
the respondent’s confidentiality, the specimen were marked with a special identification
number known only to the MLSFH Biomarker Coordinator, and only the coordinator
was able to link the plasma samples with the respondents and their personal informa-
tion. The MLSFH biomarker collectors placed the label with this identification number
on the biomarker sample. After successfully collecting and labeling the plasma sample,
the specimen collector returned it to the biomarker coordinator, who stored all plasma
samples in a cooler.
Upon returning from the field each day, the biomarker coordinator checked all sam-
ples to verify that they were collected and labeled properly; all plasma samples were
then stored in a -20◦C freezer until they were shipped to LabAnywhere. At the end of
each week, all biomarker samples were cross-checked with field records, and sent via
DHL from Malawi to the LabAnywhere laboratory in the Netherlands for testing. For
the ground and air transport to the Netherlands, the samples were packed in a special
cooler with ice packs provided by LabAnywhere, which were designed specifically for
transporting the frozen blood samples. Minimum/maximum thermometers were packed
in each transport cooler. LabAnywhere was able to analyze 92.7%, or 910 of the 982,
samples they received. None were discarded because of inadequate temperature control.
Each shipment also included a list of identification numbers, so that the entry of test
results by LabAnywhere preserved confidentiality of participants. After the biomarker
9
processing was completed by LabAnywhere (less than one week after arriving in Amster-
dam), LabAnywhere sent the results to MLSFH. LabAnywhere also prepared a database
with the assayed values and individual IDs were mapped to the extant database main-
tained by the MLSFH. After eliminating outliers that are likely to be erroneous measure-
ments (see below), the MLSFH biomarker sample includes 906 respondents with at least
one valid biomarker measurement.
Upon receiving the test results, MLSFH convened an information session in all par-
ticipating villages during which potential health concerns identified by the tests were
discussed. Individual respondents were given the option to discuss privately their results
with a health care counselor. The MLSFH also worked with local health clinics to follow
up on any potential health issues that were identified by the biomarker tests. However,
except for referrals to local health clinics, no specific treatments were provided as part of
the MLSFH biomarker study.
3.6 Transformation and cleaning of biomarker data
Some of the biomarker measures obtained by the lab fell outside the plausible range,
possibly as a result of measurement problems or instabilities of the blood samples. We
identified outliers as values that were 2 interquartile ranges below the 25th or about the
75th percentile, and replaced these with missing values. In addition, CRP values of zero
were replaced with missing. In total, the following outliers were identified: 3 for total
cholesterol (TC), 16 for HDL, 10 for LDL, 4 for triglecerides (TG), 1 for glucose (RBG),
6 for creatinine, 23 for albumin, 14 for total protein (TP), 2 for uric acid, 5 for urea
(BUN), 48 for CRP (for CRP, all of which were zero values). Log transformations of all
biomarkers are calculated since log transformations are preferable for some of the very
skewed distributions—such as for CRP—to reduce the influence of extreme values on
the results.
4. RESULTS AND DISCUSSION
Table 1 provides summary statistics for the MLSFH biomarker study population. For
906 respondents, all living in the Balaka (southern) region, at least one valid biomarker
indicator is available. The mean age is about 42–43 years, with about 50% of the study
population older than 40. The MLSFH biomarker study population is therefore relatively
old, especially when compared to the median age of the Malawi population that is around
17 years. This overrepresentation of elderly individuals in the MLSFH, which is an at-
tractive aspect for analyses using the MLSFH biomarkers, is the result of the aging of the
MLSFH panel population recruited in 1998 and the addition of a MLSFH parent sample
in 2008 that includes all respondents’ living parents. About 80% of the study population
is married, and because the original MLSFH sample included women and their current
husbands, slightly more men than women are married in the study population. As ex-
pected for the Balaka region, about 70% of respondents are Muslim, with the remainder
mostly belonging to various Christian dominations and only a small fraction reporting no
religion. More than 1/2 of women in the study population, and close to 1/3 of men in the
study population, have not attended school, and only a very small fraction has attended
10
Table 1: Summary statistics for the study population
Females Males Total
mean mean mean
(sd) (sd) (sd)
# of observations 571 335 906
Age (in 2008) 42.17 43.54 42.68
(17.75) (16.87) (17.43)
Age Group
< 30 0.296 0.307 0.300
30–39 0.205 0.131 0.178
40–49 0.186 0.152 0.173
50–59 0.144 0.209 0.168
60–69 0.0823 0.140 0.104
70+ 0.0876 0.0597 0.0773
Married (in 2008) 0.762 0.892 0.809
Muslim (vs Christian/other/none) 0.691 0.706 0.696
Schooling attainment
No school 0.575 0.320 0.483
Primary level 0.399 0.618 0.478
Secondary level 0.0256 0.0615 0.0386
Body Mass Index (BMI) (2008)
Underweight (BMI < 18.5) 0.143 0.118 0.135
Normal (18.5≤ BMI < 25) 0.750 0.837 0.777
Overweight (25≤ BMI < 30) 0.0915 0.0345 0.0737
Obese (BMI≥ 30) 0.0156 0.00985 0.0138
BMI unknown 0.215 0.396 0.282
HIV positive 0.0835 0.0496 0.0715
Subjective health
Fair/Poor 0.158 0.100 0.136
Good 0.307 0.195 0.265
Very good 0.279 0.298 0.286
Excellent 0.256 0.407 0.312
Resp.’s houshold has
access to potable water 0.843 0.880 0.857
metal roof on house 0.144 0.159 0.149
pit latrine 0.782 0.838 0.802
mosquito nets 0.816 0.828 0.821
mosquito nets treated with insecticide 0.652 0.662 0.655
Notes: Descriptive statistics are calculated for respondents with at least one
valid biomarker measure.
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secondary school.
About 12–14% of the study population is underweight with a BMI below 18.5; and
the vast majority has a normal BMI between 18.5 and 25. A small fraction of respon-
dents, somewhat more for females than for males, are somewhat overweight with a BMI
between 25 and 30, and virtually none of the MLSFH biomarker respondents are obese
with a BMI ≥ 30. Height and/or weight, and therefore BMI, is missing for about 20% of
female and 40% of male respondents.
Among women, 8% are HIV positive (based on at least one HIV positive test during
2004–2008 among respondents with at least one test in this period), and about 5% of
males are HIV positive [58, 66]. Despite the relatively high levels of morbidity and mor-
tality experienced by rural Malawians, about 50% of female and 70% of male MLSFH
biomarker respondents described their subjective health as either “very good” or “excel-
lent”, a pattern that is consistent with other low income populations [99–104].
More than 80% of MLSFH respondents have access to potable water—mostly through
a covered well or bore hole—and about 80% of respondents live in households with a pit
latrine. About 15% of respondents’ house has a metal roof, which is an indicator of rel-
ative wealth. While the majority of respondent’s households has at least one mosquito
net, only around 65% of respondent’s household have nets that have been treated with
insecticide.
Table 2 documents the means, std. deviations and percentiles of the biomarker-
based health indicators collected as part of the MLSFH. Some noteworthy patterns of
the biomarker distributions in Table 2 include:
Total Cholesterol (TC): The overall mean of total cholesterol is 110 mg/dl (median
= 108), with an interquartile range of 88.8–131. Only the four largest observations in
our sample are considered as having an elevated risk for heart disease by U.S. standards
(ie, TC > 200 mg/dl). High-density lipoprotein (HDL): The overall mean of HDL is 32
mg/dl (median = 31), with an interquartile range of 23–39. Only about 5% of women or
men have optimal levels HDL levels, defined as HDL≥ 50 mg/dl, and the majority of the
sample has levels of HDL that are too low based on U.S. clinical standards. Low-density
lipoprotein (LDL): The overall mean LDL in the overall sample is 59 mg/dl (median =
58), with an interquarile range of 42–73. By U.S. standards, only the top 5% of sampled
individuals had elevated levels of LDL (LDL > 100 mg/dl). Triglycerides (TG): The
median level of triglycerides in the MLSFH biomarker sample is 53 (mean = 59.5), with
an interquartile range of 35–71. The vast majority of respondents have TG levels well
within the normal range, and only the top 1.4% of respondents women had triglycerides
above 150 mg/dl.
Glucose (RBG): The overall mean RBG in the overall sample is 75 mg/dl (median =
68.5), with an interquarile range of 61–85. Only about 10% of respondents participants
had RBG above the 100mg/dl cut-off.
Creatinine: The median level of creatinine in the MLSFH biomarker sample was
.71 (mean = .73), with an interquartile range of .60–.83. All but the lowest quartile of
the distribution is within the normal range by U.S. standards, and thus we did not find
evidence of elevated creatinine levels in the MLSFH biomarker sample.
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Albumin (ALB): The mean and median of albumin is 3.6g/dl, with an interquartile
range of 3.4–3.9. About 38% of the sample have below normal levels of albumin. Total
protein (TP): The mean for total protein is 6.89g/dl, with a median of 6.86 and an in-
terquartile range of 6.36–7.40. All but the bottom 12% and the top 4% of the MLSFH
biomarker respondents are within the normal range for TP. Uric Acid: The median level
of uric acid in the MLSFH biomarker sample is 4.37 (mean = 4.45), with an interquartile
range of 3.70–5.21. The normal range for uric acid varies by laboratory standards, but
typically is in the range of 3.6 mg/dl and 8.3 mg/dl. Urea/Blood Urea Nitrogen (BUN):
The overall mean of blood urea nitrogen in the MLSFH biomarker sample is 10.7 mg/dl
(median = 10.4), with an interquarile range of 6.2–12.3. None of the MLSFH respon-
dents has an elevated level above 20mg/dl, which would suggest kidney problems based
on U.S. standards.
C-reactive protein (CRP): The distribution of CRP is very skewed, with the mean
level of 4.5 exceeding the median level of .70 by a factor of 6.4. The interquarile range of
CRP is .20–2.80 mg/l. Contrary to our expectation of finding widespread elevated level
of CRP in the study population, 21% of the MLSFH biomarker study population have
CRP levels that are considered normal by the U.S. standards of 3.0 mg/l.
Table 3 describes the correlation coefficients between the different biomarkers. The
correlation pattern of the MLSFH biomarkers is consistent with observations from de-
veloped countries indicating that there are significant and positive correlations among all
lipid measures (TC, HDL, LDL, TG), except for TG and HDL that are negatively corre-
lated. Glucose is positively correlated with all the lipids, except HDL, and all indicators
of renal and liver function. Albumin and creatinine are positively correlated, although
only albumin is inversely correlated with CRP. This is as expected because albumin is a
negative acute-phase protein, and the albumin concentration falls approximately 20 per-
cent during the inflammatory process. CRP is negatively correlated with the lipids TC,
HDL and LDL, and it is positively correlated with TG. It has a weak correlation with the
other biomarkers, except for albumin, with which it is slightly negatively correlated. The
generally weak correlation of the biomarkers with each other, except for lipids that are
relatively highly correlated with each other, indicates that these biomarkers are indica-
tors of different biological processes and reflect different dimensions of the respondent’s
health.
Very few of the MLSFH biomarkers fall in the high risk categories as defined by U.S.
standards, and this is particularly the case of biomarkers associated with cardiovascular
disease (CVD) such as total cholesterol, LDL, triglycerides, albumin and CRP. HDL is
the exception, where a sizable proportion of the MLSFH sample is in the high risk group.
To evaluate these findings in a comparative context, Table 4 therefore compares both the
median levels of total cholesterol, HDL, LDL, triglycerides, albumin and CRP in the
MLSFH biomarker sample, and the percentage in the high risk category for each of these
biomarkers, with the Tsimane of Bolivia, an extensively studied low income population
[19, 20, 87, 105]. The top part of the table compares the median levels, for each age
group, between these two populations, and the bottom part compares the percentage in the
high risk categories. Despite differences in the collection of blood samples and in their
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processing (venous blood for the Tsimane, and LabAnywhere kits for the MLSFH), the
age-specific patterns of the biomarkers shown above are remarkably similar. This finding
lends credibility to those obtained using the LabAnywhere system rather than collecting
venous blood as was done in the Tsimane study. The majority in either population fell
into the U.S. high-risk range only with respect to high density lipoprotein (HDL), the so-
called good cholesterol, with most respondents in both populations having too low HDL
levels.
For CRP, we can also compare the MLSFH biomarker sample to another low-CRP
population of “ultramarathon runners”. In this population, CRP can be markedly sup-
pressed, independent of adiposity, with median CRP levels being less than half of the
control median [106]. The Yakut, a subsistence population in Siberia, have also been
shown to have low CRP levels [107]. In the Yakut, the median CRP is 0.76, compared to a
median CRP of .70 in the MLSFH biomarker sample. Comparing the MLSFH biomarker
sample CRP levels to a range of countries from very modern such as the US and UK to
the Yakut and Brazil [108], the MLSFH median CRP level of .70 is clearly the lowest,
except for Japan with a median of 0.16 mg/L for men and 0.09 among women.
5. CONCLUSIONS
The MLSFH biomarker sample makes a potentially important contribution to the dif-
ferent populations in low income countries for which biomarker-based health indicators
are available. The present study confirms that the collection of such biomarkers using
the LabAnywhere system is feasible in rural sub-Saharan contexts: refusal rates to the
biomarker collection was very low in the MLSFH, and following the procedures de-
scribed above, only a small fraction of the biomarker samples could not be analyzed by
LabAnywhere. The system therefore provides an attractive alternative to the collection
of dried blood spots (DBS) and venous blood samples, providing a broader range of po-
tential biomarkers than DBS and being logistically easier than the collection of venous
blood.
Several important questions arise from the MLSFH biomarker collection and anal-
yses that need to be more carefully addressed in future research. For example, the gen-
erally very low proportion of respondents that are classified as “high risk” based on any
of the collected biomarkers is very low. The implications of this finding are currently
not well understood. Do, for instance, these inter-country differences in CRP indicate
that Malawians are in better health then the Yakut, or Aborigines in the remote North-
ern Territories of Australia [92], or in worse health than the Japanese populations [109]?
More likely, the results suggest that the conventional critical values, which are mostly
validated for developed countries, are not applicable for low income SSA contexts. For
example, very low HDL has been observed with acute or chronic inflammatory response,
as indicated by elevated levels of mean hsCRP and reduced albumin [110]. Changes in
lipoproteins are noted to occur during the acute-phase reaction to inflammation. Simi-
larly, inflammation and acute phase proteins may alter/reverse cholesterol transport by
HDL [111]. Increasingly, HDL is also thought of as a component of the innate immune
system because of its capacity to efflux cholesterol during the acute phase response [112].
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Future research using the MLSFH biomarker samples will help to answer these ques-
tions, as well as help to better understand health and disease, and their relation to social,
demographic and environmental risk factors, in Malawi and sub-Saharan Africa.
Limitations of the MLSFH biomarker data collection include that the present stude
was conducted in only one area of rural Malawi, Balaka in the south of the country. This
region is predominantly Muslim and has the highest HIV/AIDS prevalence in the coun-
try. Without evidence from other regions in Malawi, it is difficult to assess to which
extent these data reflect an overall health pattern for the rural population in the coun-
try. For instance, Muslim populations are characterized by different dietary and life style
habits, and evidence suggests that they are characterized by different health and mortal-
ity patterns compared to Christian populations [113]. Thus, it is reasonable to expect
differences in biomarker characteristics between the different Malawian regions and eth-
nic groups. Despite existing cultural, dietary and life style differences, people in rural
Malawi live at large in high poverty and have been exposed to a high risk disease envi-
ronment since birth. These latter factors may be more powerful determinants of health
patterns in a poor context compared to cultural, dietary and life style norms. Based on this
pilot biomarker data collection, we are not able to distinguish between the determinants
of health as reflected by biomarkers in Malawi.
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